Amyloid as a depot for the formulation of long-acting drugs

PLoS Biology

Volumn 6, Issue 2, 2008, Pages 0240-0252

  Maji, Samir K ^a   Schubert, David ^a   Rivier, Catherine ^b   Lee, Soon ^b   Rivier, Jean E ^b   Riek, Roland ^a,c  

^a SALK INSTITUTE FOR BIOLOGICAL STUDIES   (United States)

^b SALK INSTITUTE FOR BIOLOGICAL STUDIES   (United States)

^c Laboratory for Physical Chemistry   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

AMYLOID PROTEIN; GONADORELIN DERIVATIVE; PEPTIDE; AMYLOID; DRUG CARRIER;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DRUG FORMULATION; EMBRYO; MALE; NONHUMAN; RAT; BIOAVAILABILITY; DELAYED RELEASE FORMULATION; HUMAN;

AMYLOID; BIOLOGICAL AVAILABILITY; DELAYED-ACTION PREPARATIONS; DRUG CARRIERS; HUMANS;

EID: 40149111861     PISSN: 15449173     EISSN: 15457885     Source Type: Journal    
DOI: 10.1371/journal.pbio.0060017     Document Type: Article

References (60)

1. Chiti F, Dobson CM (2006) Protein misfolding, functional amyloid, and human disease. Annu Rev Biochem 75: 333-366.
2. Barnhart MM, Chapman MR (2006) Curli biogenesis and function. Annu Rev Microbiol 60: 131-147.
3. Iconomidou VA, Vriend G, Hamodrakas SJ (2000) Amyloids protect the silkmoth oocyte and embryo. FEBS Lett 479: 141-145.
4. Osherovich LZ, Weissman JS (2002) The utility of prions. Dev Cell 2: 143-151.
5. True HL, Lindquist SL (2000) A yeast prion provides a mechanism for genetic variation and phenotypic diversity. Nature 407: 477-483.
6. Maddelein ML, Dos Reis S, Duvezin-Caubet S, Coulary-Salin B, Saupe SJ (2002) Amyloid aggregates of the HET-s prion protein are infectious. Proc Natl Acad Sci U S A 99: 7402-7407.
7. Fowler DM, Koulov AV, Alory-Jost C, Marks MS, Balch WE, et al. (2006) Functional amyloid formation within mammalian tissue. PLoS Biol 4: e6. doi:10.1371/journal.pbio.0040006
8. Hardy J, Selkoe DJ (2002) The amyloid hypothesis of Alzheimer's disease: progress and problems on the road to therapeutics. Science 297: 353-356.
9. Guijarro JI, Sunde M, Jones JA, Campbell ID, Dobson CM (1998) Amyloid fibril formation by an SH3 domain. Proc Natl Acad Sci U S A 95: 4224-4228.
10. Chiti F, Webster P, Taddei N, Clark A, Stefani M, et al. (1999) Designing conditions for in vitro formation of amyloid protofilaments and fibrils. Proc Natl Acad Sci U S A 96: 3590-3594.
11. Dobson CM (2001) The structural basis of protein folding and its links with human disease. Philos Trans R Soc Lond B Biol Sci 356: 133-145.
12. Sunde M, Blake C (1997) The structure of amyloid fibrils by electron microscopy and X-ray diffraction. Adv Protein Chem 50: 123-159.
13. Sunde M, Serpell LC, Bartlam M, Fraser PE, Pepys MB, et al. (1997) Common core structure of amyloid fibrils by synchrotron X-ray diffraction. J Mol Biol 273: 729-739.
14. Klunk WE, Jacob RF, Mason RP (1999) Quantifying amyloid by Congo red spectral shift assay. Methods Enzymol 309: 285-305.
15. LeVine H (1999) Quantification of β-sheet amyloid fibril structures with thioflavin T. Methods Enzymol 309: 274-284.
16. Harper JD, Lansbury PT Jr (1997) Models of amyloid seeding in Alzheimer's disease and scrapie: mechanistic truths and physiological consequences of the time-dependent solubility of amyloid proteins. Annu Rev Biochem 66: 385-407.
17. Reches M, Gazit E (2003) Casting metal nanowires within discrete self-assembled peptide nanotubes. Science 300: 625-627.
18. Scheibel T, Parthasarathy R, Sawicki G, Lin XM, Jaeger H, et al. (2003) Conducting nanowires built by controlled self-assembly of amyloid fibers and selective metal deposition. Proc Natl Acad Sci U S A 100: 4527-4532.
19. MacPhee CEW, Woolfson DN (2004) Engineered and designed peptide-based fibrous biomaterials. Curr Opin Solid State Mat Sci 8: 141-149.
20. Scheibel T (2005) Protein fibers as performance proteins: new technologies and applications. Curr Opin Biotechnol 16: 427-433.
21. Holmes TC, de Lacalle S, Su X, Liu G, Rich A, et al. (2000) Extensive neurite outgrowth and active synapse formation on self-assembling peptide scaffolds. Proc Natl Acad Sci U S A 97: 6728-6733.
22. Smith JF, Knowles TP, Dobson CM, Macphee CE, Welland ME (2006) Characterization of the nanoscale properties of individual amyloid fibrils. Proc Natl Acad Sci U S A 103: 15806-15811.
23. Langer R (1990) New methods of drug delivery. Science 249: 1527-1533.
24. Fowler SB, Poon S, Muff R, Chiti F, Dobson CM, et al. (2005) Rational design of aggregation-resistant bioactive peptides: reengineering human calcitonin. Proc Natl Acad Sci U S A 102: 10105-10110.
25. Matsuo H, Baba Y, Nair RM, Arimura A, Schally AV (1971) Structure of the porcine LH- and FSH-releasing hormone. I. The proposed amino acid sequence. Biochem Biophys Res Commun 43: 1334-1339.
26. Herbst KL (2003) Gonadotropin-releasing hormone antagonists. Curr Opin Pharmacol 3: 660-666.
27. Karten MJ, Rivier JE (1986) Gonadotropin-releasing hormone analog design. Structure-function studies toward the development of agonists and antagonists: rationale and perspective. Endocr Rev 7: 44-66.
28. Lunenfeld B, Editor (1999) GnRH analogues. the state of the art at the millennium. Pearl River (New York): The Parthenon Publishing Group. 136 p.
29. Jiang G, Stalewski J, Galyean R, Dykert J, Schteingart C, et al. (2001) GnRH antagonists: a new generation of long acting analogues incorporating pureido-phenylalanines at positions 5 and 6. J Med Chem 44: 453-467.
30. Broqua P, Riviere PJ, Conn PM, Rivier JE, Aubert ML, et al. (2002) Pharmacological profile of a new, potent, and long-acting gonadotropin-releasing hormone antagonist: degarelix. J Pharmacol Exp Ther 301: 95-102.
31. Powell MF, Fleitman J, Sanders LM, Si VC (1994) Peptide liquid crystals: inverse correlation of kinetic-formation and thermodynamic stability in aqueous solution. Pharm Res 11: 1352-1354.
32. Cannon JB, Krill SL, Porter WR (1995) Physicochemical properties of A-75998, an antagonist of luteinizing hormone releasing hormone. J Pharm Sci 84: 953-958.
33. Tan MM, Corley CA, Stevenson CL (1998) Effect of gelation on the chemical stability and conformation of leuprolide. Pharm Res 15: 1442-1448.
34. Jiang G, Gavini E, Dani BA, Murty SB, Schrier B, et al. (2002) Identification and determination of GnRH antagonist gelling at injection site. Int J Pharm 233: 19-27.
35. Klunk WE, Pettegrew JW, Abraham DJ (1989) Quantitative evaluation of congo red binding to amyloid-like proteins with a β-pleated sheet conformation. J Histochem Cytochem 37: 1273-1281.
36. Plourde F, Motulsky A, Couffin-Hoarau AC, Hoarau D, Ong H, et al. (2005) First report on the efficacy of l-alanine-based in situ-forming implants for the long-term parenteral delivery of drugs. J Control Release 108: 433-441.
37. Tennent GA, Lovat LB, Pepys MB (1995) Serum amyloid P component prevents proteolysis of the amyloid fibrils of Alzheimer disease and systemic amyloidosis. Proc Natl Acad Sci U S A 92: 4299-4303.
38. Suk JY, Zhang F, Balch WE, Linhardt RJ, Kelly JW (2006) Heparin accelerates gelsolin amyloidogenesis. Biochemistry 45: 2234-2242.
39. Westermark GT, Johnson KH, Westermark P (1999) Staining methods for identification of amyloid in tissue. Methods Enzymol 309: 3-25.
40. Dische FE, Wernstedt C, Westermark GT, Westermark P, Pepys MB, et al. (1988) Insulin as an amyloid-fibril protein at sites of repeated insulin injections in a diabetic patient. Diabetologia 31: 158-161.
41. Betts PR, Jefferson IG, Swift PG (2002) Diabetes care in childhood and adolescence. Diabet Med 19: 61-65.
42. Samant MP, White R, Hong DJ, Croston G, Conn PM, et al. (2007) Structure-activity relationship studies of gonadotropin-releasing hormone antagonists containing S-aryl/alkyl norcysteines and their oxidized derivatives. J Med Chem. 50: 2067-2077.
43. Samant MP, Hong DJ, Croston G, Rivier C, Rivier J (2006) Novel analogues of degarelix incorporating hydroxy-, methoxy-, and pegylated-urea moieties at positions 3, 5, 6 and the N-terminus. Part III. J Med Chem 49: 3536-3543.
44. Behl C, Davis JB, Lesley R, Schubert D (1994) Hydrogen peroxide mediates amyloid β-protein toxicity. Cell 77: 817-827.
45. Wright CF, Teichmann SA, Clarke J, Dobson CM (2005) The importance of sequence diversity in the aggregation and evolution of proteins. Nature 438: 878-881.
46. Han HY, Weinreb PH, Lansbury PT (1995) The core Alzheimer's peptide NAC forms amyloid fibrils which seed and are seeded by β-amyloid: is NAC a common trigger or target in neurodegenerative disease? Chem Biol 2: 163-169.
47. Kessler JC, Rochet JC, Lansbury PT (2003) The N-terminal repeat domain of α-synuclein inhibits β-sheet and amyloid fibril formation. Biochemistry 42: 672-678.
48. Langer R (1998) Drug delivery and targeting. Nature 392: 5-10.
49. Putney SD, Burke PA (1998) Improving protein therapeutics with sustained-release formulations. Nat Biotechnol 16: 153-157.
50. Jen A, Madorin K, Vosbeck K, Arvinte T, Merkle HP (2002) Transforming growth factor β-3 crystals as reservoirs for slow release of active TGF-β3. J Control Release 78: 25-34.
51. Brader ML, Sukumar M, Pekar AH, McClellan DS, Chance RE, et al. (2002) Hybrid insulin cocrystals for controlled release delivery. Nat Biotechnol 20: 800-804.
52. Langer R (2001) Drug delivery. Drugs on target. Science 293: 58-59.
53. Orive G, Hernandez RM, Rodriguez Gascon A, Dominguez-Gil A, Pedraz JL (2003) Drug delivery in biotechnology: present and future. Curr Opin Biotechnol 14: 659-664.
54. Richards Grayson AC, Choi IS, Tyler BM, Wang PP, Brem H, et al. (2003) Multi-pulse drug delivery from a resorbable polymeric microchip device. Nat Mater 2: 767-772.
55. Guptabansal R, Frederickson RCA, Brunden KR (1995) Proteoglycan-mediated inhibition of Aβ proteolysis: a potential cause of senile plaque accumulation. J Biol Chem 270: 18666-18671.
56. Cotman SL, Halfter W, Cole GJ (2000) Agrin binds to β-amyloid (Aβ), accelerates ab fibril formation, and is localized to Aβ deposits in Alzheimer's disease brain. Mol Cell Neurosci 15: 183-198.
57. Van Poppel H, De La Rosette J, Persson B, Jensen JK, Olesen TK (2006) A one-year, multicentre, randomised study of degarelix, a gonadatrophin-releasing bord-7-0910 hormone (GnRH) receptor blocker, in prostate cancer patients. 21st Annual Meeting of the European Association of Urology (EAU), 5-8 April 2006, Paris, France. Eur Urol Suppl 5: 251
58. O'Nuallain B, Shivaprasad S, Kheterpal I, Wetzel R (2005) Thermodynamics of Aβ(1-40) amyloid fibril elongation. Biochemistry 44: 12709-12718.
59. Rivier C, Grigoriadis D, Rivier J (2003) Role of corticotropin releasing factor receptors type 1 and 2 in modulating the rat adrenocorticotropin response to stressors. Endocrinology 144: 2396-2403.
60. Rivier C (1995) Decreased plasma gonadotropin and testosterone levels in arthritic rats: are corticosteroids involved? Endocrine 3: 383-390.